Phase 2 Chronic Rhinosinusitis Trial, By Invitation (NCT06914908)

Phase 2 Chronic Rhinosinusitis Trial, By Invitation NCT06914908 Sponsor: Sanofi Condition: Chronic Rhinosinusitis

Printed from Voxsanity (voxsanity.com.au) — NCT06914908 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Chronic Rhinosinusitis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You must have already completed the full treatment and follow-up period (including the final end-of-study visit) in the related lunsekimig parent study.
You must currently be using a mometasone furoate nasal spray (a type of steroid nasal spray) as part of your treatment.
You must be willing and able to attend the required study visits and follow the study procedures.

Who may not be able to join:

You may not be able to join if you have previously had an allergic or bad reaction to lunsekimig or any of its ingredients, or if you have another allergy that the study doctor believes makes it unsafe for you to participate.
You may not be able to join if you are currently taking part in any other clinical study or research study (aside from the parent study this trial is linked to).
You may not be able to join if you experienced a side effect or serious health problem during the parent study that was believed to be caused by lunsekimig, and the study doctor feels that continuing the treatment could put you at unreasonable risk.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06914908

Sponsor: Sanofi

Phase: Phase 2

Status: By Invitation

Condition: Chronic Rhinosinusitis

More information: https://clinicaltrials.gov/study/NCT06914908

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You must have already completed the full treatment and follow-up period (including the final end-of-study visit) in the related lunsekimig parent study.
You must currently be using a mometasone furoate nasal spray (a type of steroid nasal spray) as part of your treatment.
You must be willing and able to attend the required study visits and follow the study procedures.

Who may not be able to join:

You may not be able to join if you have previously had an allergic or bad reaction to lunsekimig or any of its ingredients, or if you have another allergy that the study doctor believes makes it unsafe for you to participate.
You may not be able to join if you are currently taking part in any other clinical study or research study (aside from the parent study this trial is linked to).
You may not be able to join if you experienced a side effect or serious health problem during the parent study that was believed to be caused by lunsekimig, and the study doctor feels that continuing the treatment could put you at unreasonable risk.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

By Invitation

Phase

Phase 2

Sponsor

Sanofi

Registry

ClinicalTrials.gov

Start date

12 May 2025

Est. completion

29 January 2031

Where this trial is recruiting

🇦🇷 Argentina 🇧🇪 Belgium 🇧🇬 Bulgaria 🇵🇱 Poland 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Incidence of participants with treatment-emergent adverse events (TEAEs) including adverse events of special interest (AESI), and serious adverse events (SAEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov